Welcome to LEE'S PHARM.
I'm sorry that our content requires Adobe Flash Player.

get flash logo

Please download flash player here

2018.12.20 Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia
2018.09.06 SillaJen and Lee’s Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
2018.02.14 GC Pharma and Lee’s Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
2018.02.08 CHINA ONCOLOGY FOCUS LIMITED RECEIVES APPROVAL BY CHINESE AUTHORITIES TO BEGIN CLINICAL TRIALS IN THREE SEPARATE CANCER INDICATIONS USING SORRENTO’S ANTI-PD-L1 MONOCLONAL ANTIBODY
2017.11.22 Eleison Pharmaceuticals to Partner with China Oncology Focus Limited, an Affiliate of Lee’s Pharmaceutical Holdings, to Develop and Commercialize Glufosfamide for the China Market
2017.11.21 Shenogen Pharma and Lee’s Pharm entered into a Collaboration Agreement for a Combination Product for Treatment of Late Stage Cancers
2017.11.02 Windtree and Lee’s Pharm Close $10 Million Share Purchase Agreement Giving Lee’s Pharm Controlling Interest in Windtree
2017.10.04 Appointment Of Ms. Zhang Zhen Hua, Ada As Group Director Of Human Resources And Development Of Lee’s Pharmaceutical Holdings Limited
2017.08.21 Zingo® for Needle-free Local Analgesia is approved by Hong Kong Department of Health
2017.07.26 SillaJen and Lee’s Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

© Lee's Pharmaceutical Holdings Limited     Terms of Use   |   Privacy Statement Designed by YSD